Mettrum Health Corp. (TSXV:MT.V) announce that the Company has received an amendment to its license to include both the production and sale of medical cannabis and extracts from Health Canada under the Marihuana for Medical Purposes Regulations at its 60,000 square foot production and distribution facility located in Bowmanville, Ontario.
As quoted in the press release:
Under the MMPR, the license was upgraded from production only and provides Mettrum with the ability to produce and sell dried medical cannabis as well as cannabis extracts from the Bowmanville South facility. This provides the company with total licensed production capacity of 3,500 kg and licensed sales capacity of 3,550 kg of dried cannabis and production and sales capacity of 1,906 kg of cannabis extracts. The Bowmanville South facility has total production capacity on a fully built out basis of 8,000 kg of cannabis representing $60 million in sales plus potential extracts.
Mettrum has three fully licensed facilities to produce and sell dried cannabis and cannabis extracts, with a production capacity on a fully built out basis of 12,000 kg per year. As one of Canada’s largest producers and sellers of medical cannabis, Mettrum is exceptionally well-positioned to serve the needs of a growing and regulated market.
Mettrum Health CEO, Michael Haines, stated:
This latest milestone is significant as we can now transition our distribution hub from our original facility at Bennett Road North, to our largest facility down the road. We continue to advance our business plan. These latest amendments will contribute to our continually improving operational efficiency and margins.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.